

February 24, 2022



## **BiomX Presenting at Three Upcoming Investor Conferences**

*2022 Aegis Virtual Conference on February 24, 2022*

*Chardan 4<sup>th</sup> Annual Microbiome Medicines Summit on March 1, 2022*

*Oppenheimer & Co. 32<sup>nd</sup> Annual Virtual Healthcare Conference on March 17, 2022*

NESS ZIONA, Israel--(BUSINESS WIRE)-- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the 2022 Aegis Virtual Conference on February 24, 2022, the Chardan 4<sup>th</sup> Annual Microbiome Medicines Summit on March 1, 2022 and the Oppenheimer & Co. 32<sup>nd</sup> Annual Healthcare Conference on March 17, 2022.

### **2022 Aegis Virtual Conference – February 23-25, 2022**

Date & Time: Thursday, March 24, 2:30 PM EST  
Presenter: Jonathan Solomon  
Conference registration: [Link](#)

### **Chardan 4<sup>th</sup> Annual Microbiome Medicines Summit – March 1, 2022**

Date & Time: Tuesday, March 1, 8:30 AM EST  
Presenter: Jonathon Solomon  
Conference registration: [Link](#)

### **Oppenheimer & Co. 32<sup>nd</sup> Annual Healthcare Conference – March 15-17, 2022**

Date & Time: Thursday, March 17, 2:00 PM EST  
Presenter: Jonathan Solomon  
Conference registration: [Link](#)

Live webcasts of presentations will also be accessible through the Investors section of the Company's website at <https://ir.biomx.com/news-events/ir-calendar>. Following the events, the webcasts will be archived on the BiomX website.

**About BiomX Inc.**

BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit [www.BiomX.com](http://www.BiomX.com)

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20220224005117/en/>

#### BiomX Contacts

##### Investor Relations:

LifeSci Advisors, LLC

John Mullaly

(617)-698-9253

[jmullaly@lifesciadvisors.com](mailto:jmullaly@lifesciadvisors.com)

BiomX, Inc.

Anat Primovich

Corporate Project Manager

+972 (50) 697-7228

[anatp@biomx.com](mailto:anatp@biomx.com)

Source: BiomX Inc.